Emg827
发表于 2025-3-25 05:10:14
http://reply.papertrans.cn/87/8685/868499/868499_21.png
烦躁的女人
发表于 2025-3-25 08:46:02
Sunitinib in the Treatment of Advanced Solid Tumors,r (PDGFR) alpha and beta, c-kit, and other receptors. These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC), unresectable gastrointestinal stromal tumors (GIST), and well-differentiated advanced pancreatic neuroendocrine tumors (PNET). Though activi
做方舟
发表于 2025-3-25 13:27:37
http://reply.papertrans.cn/87/8685/868499/868499_23.png
积习难改
发表于 2025-3-25 18:51:52
Crizotinib,ere is convincing clinical evidence for the effectiveness in non-small-cell lung cancer (NSCLC) harboring EML4-ALK rearrangements resulting in constitutional activation of the ALK-RTK. The drug is approved for this entity, which represents no more than 3–5 % of all NSCLC. However, in this population
商议
发表于 2025-3-25 23:46:00
http://reply.papertrans.cn/87/8685/868499/868499_25.png
fleeting
发表于 2025-3-26 00:55:44
Vemurafenib,protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40 % of melanoma patients and BRAF V600K mutations in ~5 % of melanoma patients. Activation of the MAPK pathway results in continuous stimulation of cell proliferation and inhibits programmed cell death
Cosmopolitan
发表于 2025-3-26 06:11:36
http://reply.papertrans.cn/87/8685/868499/868499_27.png
细微差别
发表于 2025-3-26 11:46:53
Trametinib,ding survival, differentiation, proliferation, motility, and angiogenesis. Therefore, MEK inhibition was recognized as a promising target for antineoplastic therapy. While multiple MEK inhibitors have been tested clinically only trametinib (GSK1120212), an oral MEK inhibitor which is selective for M
constitutional
发表于 2025-3-26 14:13:07
Ruxolitinib,treatment of myelofibrosis, which is characterized, biologically, by the activation of the JAK-STAT pathway and, clinically, by bone marrow fibrosis, splenomegaly, abnormal blood counts, and poor quality-of-life through associated symptoms. Ruxolitinib treatment results in a meaningful reduction in
精美食品
发表于 2025-3-26 20:33:03
Ibrutinib,role in BCR signaling. Ibrutinib (PCI-32765) is a novel agent which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency. Preliminary data from phase I and ongoing phase II trials have proven very promising so far. It suggests the subst